Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16739279 | 0.84 | KCNH2 (0.54) | KCNH2KCNJ1MAOAHTR2AHTR2C | |
| SCHEMBL7583274 | 0.84 | SLC6A3 (0.63) | KCNH2SLC6A3 | |
| SCHEMBL7422143 | 0.83 | MAPT (0.53) | — | |
| SCHEMBL5745400 | 0.79 | KCNJ1 (0.61) | KCNH2KCNJ1MAOAHTR2AHTR2C | |
| SCHEMBL7423301 | 0.79 | ALDH1A1 (0.50) | — | |
| SCHEMBL23377845 | 0.78 | HRH3 (0.62) | KCNH2KCNJ1MAOAHTR2AHTR2C | |
| SCHEMBL23377646 | 0.78 | HRH3 (0.68) | KCNH2KCNJ1MAOAHTR2AHTR2C | |
| SCHEMBL4069868 | 0.78 | HTR2A (0.59) | KCNH2KCNJ1HTR2AHTR2CHTR7 | |
| SCHEMBL24322840 | 0.77 | KCNH2 (0.59) | KCNH2KCNJ1MAOAHTR2AHTR2C | |
| SCHEMBL38658212 | 0.77 | SIGMAR1 (0.43) | KCNH2KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4119141-A1 | NELOTANSERIN FOR THE PROPHYLAXIS AND TREATMENT OF REM SLEEP BEHAVIOR DISORDER | Axovant Sciences GmbH (CH) | 2023-01-18 | — | — | EP | disclosed |
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-01 | — | — | US | disclosed |
| US-7312342-B2 | Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)-methanone and salts thereof | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2007-12-25 | — | — | US | disclosed |
| CN-1213029-C | Process for the preparation of (3-cyano-1H-indol-7-yl) (4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof | MERCH PATENT GMBH (DE) | 2005-08-03 | — | — | CN | disclosed |
| CN-1487923-A | Process for the preparation of (3-cyano-1H-indol-7-yl) (4- (4-fluorophenethyl) piperazin-1-yl) -methanone and salts thereof | Ĭ��ר���ɷ�����˾ | 2004-04-07 | — | — | CN | disclosed |
| CN-1487923-A | Process for the preparation of (3-cyano-1H-indol-7-yl) (4- (4-fluorophenethyl) piperazin-1-yl) -methanone and salts thereof | Ĭ��ר���ɷ�����˾ | 2004-04-07 | — | — | CN | disclosed |
| US-20040063723-A1 | Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)- methanone and salts thereof | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| EP-1353906-A1 | PROCESS FOR THE PREPARATION OF (3-CYANO-1H-INDOL-7-YL)(4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL)-METHANONE AND SALTS THEREOF | MERCK PATENT GmbH (DE) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002059092-A1 | PROCESS FOR THE PREPARATION OF (3-CYANO-1H-INDOL-7-YL)(4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL)-METHANONE AND SALTS THEREOF | MERCK PATENT GMBH (DE) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063723-A1 | Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)- methanone and salts thereof | TPH1, TPH2, IDO1 | KCNH2 153/4885KCNJ1 143/4885MAOA 97/4885 |
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | KCNH2 4403/4885KCNJ1 4716/4885MAOA 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.